Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells

被引:27
作者
Zhang, You-Cheng [1 ]
Wang, Xiao-Peng
Zhang, Ling-Yi
Song, Ai-Lin
Kou, Zhi-Min
Li, Xu-Sheng
机构
[1] Lanzhou Univ Second Hosp, Dept Surg, Lanzhou 730030, Gansu Province, Peoples R China
[2] Gansu Prov Peoples Hosp, Dept Surg, Lanzhou 730030, Gansu Province, Peoples R China
关键词
insulin-like growth factor; receptor; monoclonal antibody; hepatocellular carcinoma cell; target therapy;
D O I
10.3748/wjg.v12.i25.3977
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To study the expression level and localization of insulin-like growth factor -I receptor (IGF-IR) in HepG2 cells and Chang liver cells, and to observe the effect of anti-IGF-IR monoclonal antibody (alpha IR3) on the growth of HepG2 cells. METHODS: The expression of IGF-IR in HepG2 cells and Chang liver cells was detected by immunohistochemistry. The influences of aIR3 on proliferation and apoptosis were examined by the 3- (4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and electron microscopy, respectively. Flow cytometry (FCM) was applied for the analysis of cell cycle and apoptosis was observed under electron microscope. RESULTS: IGF-IR was located in the membranes of both HepG2 and Chang liver cell lines, and the expression level of IGF-IR was higher in HepG2 cells than in Chang liver cells. Treated with 0.1 mu g/mL alpha IR3 for 48 h in vitro, the cell growth index (GI) of HepG2 cells was significantly higher than that of control (103.41% vs 100%, P < 0.01). However, the alpha IR3 for 24 h at final concentration of 4.0 mu g/mL made the GI of HepG2 cells lower than that of control (93.37% vs 100%, P < 0.01). Compared with control, treated with aIR3 for 48 h at final concentrations ranging from 1.0 mu g/mL to 4.0 mu g/mL markedly reduced the GIs of HepG2 cells (97.63%, 97.16%, 95.13%, 92.53% vs 100%, P < 0.05 or P < 0.01), treated with alpha IR3 for 72 h at final concentrations ranging from 0.2 mu g/mL to 4.0 mu g/mL decreased the GIs of HepG2 cells obviously (95%, 91.63%, 90.77%, 89.84%, 88.51% vs 100%, P < 0.01), and treated with aIR3 for 96 h at final concentrations ranging from 0.5 mu g/mL to 4.0 mu g/mL made GIs of HepG2 cells lower significantly (88.86%, 83.97%, 79.81%, 77.24%, 70.51% vs 100%, P < 0.05 or P < 0.01). Moreover, treated with alpha IR3 from 24 h to 96 h at final concentrations ranging from 0.2 mu g/mL to 4.0 mu g/mL reduced the GI of HepG2 cells from 97.63% to 70.51% in a close- and time-dependent manner. Also, alpha IR3 treatment for 72 h at final concentration from 0.5 mu g/mL to 2.0 mu g/mL increased the proportion of G0/G1 phase cells(61.73%, 67.1%, 83.7%,76.87% vs 44.47%, P < 0.01) and significantly decreased that of S phase cells(28.63%, 25.13%, 15.63%, 23.13% vs 53.17%, P < 0.01), in contrast to the proportion of G2/M phase cells. The apoptotic rates of HepG2 cells were increased more than that of control (7.83%, 16.13%, 21.1%, 37.73% vs 4.13%, P < 0.01). CONCLUSION: The malignant cell phenotype of human hepatocarcinoma cell is related to overexpression of IGF-IR. The blockage of IGF-IR with alpha IR3 may contribute to the inhibition of proliferation and induction of apoptosis in HepG2 cells. (C) 2006 The WJG Press. All rights reserved.
引用
收藏
页码:3977 / 3982
页数:6
相关论文
共 30 条
[1]
Structure and function of the type 1 insulin-like growth factor receptor [J].
Adams, TE ;
Epa, VC ;
Garrett, TPJ ;
Ward, CW .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (07) :1050-1093
[2]
BASERGA R, 1995, CANCER RES, V55, P249
[3]
Benini S, 2001, CLIN CANCER RES, V7, P1790
[4]
Inhibition of the type 1 insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy [J].
Brodt, P ;
Samani, A ;
Navab, R .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1101-1107
[5]
Cellular survival: a play in three Akts [J].
Datta, SR ;
Brunet, A ;
Greenberg, ME .
GENES & DEVELOPMENT, 1999, 13 (22) :2905-2927
[6]
The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update [J].
El-Serag, H ;
Davila, JA ;
Petersen, NJ ;
McGlynn, KA .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (10) :817-823
[7]
Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States [J].
El-Serag, HB ;
Mason, AC ;
Key, C .
HEPATOLOGY, 2001, 33 (01) :62-65
[8]
Induction of apoptosis in rat hepatocarcinoma cells by expression of IGF-I antisense c-DNA [J].
Ellouk-Achard, S ;
Djenabi, S ;
De Oliveira, GA ;
Desauty, G ;
Duc, HT ;
Zohair, M ;
Trojan, J ;
Claude, JR ;
Sarasin, A ;
Lafarge-Frayssinet, C .
JOURNAL OF HEPATOLOGY, 1998, 29 (05) :807-818
[9]
Hailey J, 2002, MOL CANCER THER, V1, P1349
[10]
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma [J].
Höpfner, M ;
Sutter, AP ;
Huether, A ;
Schuppan, D ;
Zeitz, M ;
Scherübl, H .
JOURNAL OF HEPATOLOGY, 2004, 41 (06) :1008-1016